EGFR and adenocarcinoma: Dysregulation of the mTOR pathway is more common in squamous cell lung cancer than in adenocarcinoma, and patients with mutant EGFR always show abnormal PI3K/AKT/mTOR activation, which leads to resistance to clinical treatment with EGFR-tyrosine kinase inhibitor (EGFR-TKI) (38).